CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

XRC Labs

Al Sambar, General Partner

Recent Trends In The Startup Landscape

Al Sambar

Al Sambar

1. In your opinion, how has the startup landscape evolved over the years? What are some of the advantages of the current technological evolution?


Well, I’m in the early-stage VC world and tend to take that lens. I’ve been at it since the aughts, so change is relative - it just seems to keep accelerating. I see current trends taking place in three big areas.


• Fund availability


There’s a rich environment for an early[1]stage startup to raise capital. Young startups can now get capital from crowdsource funding, new types of debt funds, and of course from venture funds like XRC Labs.


• Areas of capital investment


Obviously the ‘hot’ topic areas change over time, influenced by larger tech trends. On the challenge side, this year we’ve seen changes in Apple and other ecosystem players resulting in higher customer acquisition costs (CAC) on digital channels. This means those DTC brand founders have faced some headwinds fundraising. But on the positive side, startups creating new platforms to make marketing easy across many channels or those pur[1]suing darn near anything related to NFT/crypto and metaverse-related technologies…all have had a great tailwind in ‘21. Lastly, we still see many areas that continue to be strong in retail and consumer ventures (supply chain, sustain[1]ability, consumerized healthcare, new commerce channels like rental & recommence, etc.). Seems like anything enabling more channels for commerce has done well in ‘21.


• Web 2.0 to 3.0 Evolution…not so fast!


There is a lot of discussion and investing around web 3.0 and full DApps (Distributed Applications). But in the retail and consumer venture segment, we are still in a tech renaissance for folks creating businesses using the emergent tools from web 2.0: headless commerce, no-code platforms, API no-code backends, AI marketing automation, etc. If you can dream up a business idea today, you can create it without a big dedicated tech team. That really makes it wonderful for investors looking for simple, quick validation of a value proposition and business model; and particularly wonderful for imaginative, creative founders.


2. What according to you are some of the challenges plaguing the startup landscape and how can they be effectively mitigated?


The most obvious challenge would be the CAC inflation I mentioned earlier. For DTC brands, it’s simply a non-starter to buy a customer base these days. You need to either have someone else buy it for you with a strategic partnership or platform business model. Or, you need to have a vehicle for creating significant organic traffic with great retention. We are still willing to invest in direct businesses, but these days we expect the CAC problem to be solved very early in the life of the business. The second issue is that venture funds aren’t as eager to invest in direct brands as compared to tech or platform businesses, because exit valuations are so much higher for the latter.


The solution for this is probably mixing in debt capital with venture capital to grow great new direct brands.


3. What are a few technological trends influencing startups today? What are some of the best practices businesses should adopt today to steer ahead of competitors?


I see a lot of startups! And there is no one magic tech. I see impressive companies leveraging all manner of new tech and platforms, but the ones I invest in have placed a bet. They’ve figured out where their customers are and how to connect with them on these channels. Most commonly they’re using tech stacks that look VERY adaptable, so headless commerce is common, as is efficient use of AI and no[1]code tools. These modern tools replace large developer teams and heavy agency spend.


4. Do you have any advice for industry veterans or budding entrepreneurs from the startup space?


Sure, entrepreneurs usually struggle for one of two reasons. Either investors fail to understand or agree with their vision, or investors lack confidence in their ability to execute that vision.


I advise budding entrepreneurs to practice conveying their vision in a succinct way. At XRC we call this an “elevator pitch” which is two to three sentences explaining what your company is and why it’s different from others in the space. This will serve you well when pitching investors.


We see so many startups trying to solve the same or similar problems, so we’re always looking for founders with a strategic advantage, a secret monopoly, a hidden secret key… magic beans


Finally and most importantly, even if you have a great vision, investors need some ‘magic beans’. We see so many startups trying to solve the same or similar problems, so we’re always looking for founders with a strategic advantage, a secret monopoly, a hidden secret key… magic beans. Please explain to me your magic beans!


For budding entrepreneurs, especially those in underrepresented communities, know that there really are many people out there who love to help founders. I encourage you to sign up for XRC Labs’ office hours which creates an initial connection to the VC world and advisors in the retail tech and consumer goods sectors.


During office hour sessions, we advise and help founders on various topics, including investor decks, fundraising, and growth. Startups that participate in this program are not obligated to join XRC, but we hope the guidance will better equip founders to grow and scale their businesses.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.
The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://biotech-startups.lifesciencesreview.com/leadership-perspective/recent-trends-in-the-startup-landscape-nwid-814.html